NovoCure Ltd (NVCR)
12.11
+0.28
(+2.37%)
USD |
NASDAQ |
Apr 23, 15:25
NovoCure Revenue (Quarterly): 133.78M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 133.78M |
| September 30, 2023 | 127.32M |
| June 30, 2023 | 126.05M |
| March 31, 2023 | 122.18M |
| December 31, 2022 | 128.43M |
| September 30, 2022 | 131.00M |
| June 30, 2022 | 140.87M |
| March 31, 2022 | 137.55M |
| December 31, 2021 | 133.21M |
| September 30, 2021 | 133.61M |
| June 30, 2021 | 133.52M |
| March 31, 2021 | 134.70M |
| December 31, 2020 | 143.95M |
| September 30, 2020 | 132.66M |
| June 30, 2020 | 115.92M |
| March 31, 2020 | 101.83M |
| December 31, 2019 | 99.23M |
| September 30, 2019 | 92.06M |
| June 30, 2019 | 86.71M |
| Date | Value |
|---|---|
| March 31, 2019 | 73.31M |
| December 31, 2018 | 69.67M |
| September 30, 2018 | 64.76M |
| June 30, 2018 | 61.51M |
| March 31, 2018 | 52.12M |
| December 31, 2017 | 53.66M |
| September 30, 2017 | 50.11M |
| June 30, 2017 | 38.38M |
| March 31, 2017 | 34.88M |
| December 31, 2016 | 30.24M |
| September 30, 2016 | 21.67M |
| June 30, 2016 | 17.92M |
| March 31, 2016 | 13.05M |
| December 31, 2015 | 12.38M |
| September 30, 2015 | 8.953M |
| June 30, 2015 | 6.543M |
| March 31, 2015 | 5.208M |
| December 31, 2014 | 3.801M |
| September 30, 2014 | 4.374M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
86.71M
Minimum
Jun 2019
143.95M
Maximum
Dec 2020
123.93M
Average
131.00M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| AtriCure Inc | 106.54M |
| NeuroMetrix Inc | 1.318M |
| Repligen Corp | 155.74M |
| Teleflex Inc | 773.91M |
| Perspective Therapeutics Inc | -5.239M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -47.08M |
| Total Expenses (Quarterly) | 185.50M |
| EPS Diluted (Quarterly) | -0.45 |
| Enterprise Value | 925.12M |
| Gross Profit Margin (Quarterly) | 75.67% |
| Profit Margin (Quarterly) | -35.19% |
| Earnings Yield | -16.10% |
| Normalized Earnings Yield | -16.10 |